(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 518.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.68%.
Cytokinetics's revenue in 2025 is $3,219,000.On average, 10 Wall Street analysts forecast CYTK's revenue for 2025 to be $5,462,407,113, with the lowest CYTK revenue forecast at $472,056,960, and the highest CYTK revenue forecast at $19,425,143,904. On average, 9 Wall Street analysts forecast CYTK's revenue for 2026 to be $36,300,000,082, with the lowest CYTK revenue forecast at $17,619,526,032, and the highest CYTK revenue forecast at $49,211,938,080.
In 2027, CYTK is forecast to generate $96,768,254,387 in revenue, with the lowest revenue forecast at $48,788,266,958 and the highest revenue forecast at $171,675,314,928.